Clinical trials: Relapsed
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
The main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic…
- Trial name
- CD7-CAR01 (NCT06064903)
- Testing
- CD7-CART01
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Relapsing-Remitting Multiple Sclerosis
GER-009-06-AVX Early Therapy in Multiple Sclerosis
This study is being done to increase awareness for early therapy with Avonex for Multiple Sclerosis (MS) and the cognitive dysfunction that accompanies MS, and to record safety data for Avonex.
- Trial name
- FIT (NCT00492570)
- Volunteers
- 230 people
- Sponsor
- Biogen
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer
RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00823524
- Testing
- donor natural killer cell infusion
- Where
- South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
AML, Childhood
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
- Trial name
- NCT05077423
- Testing
- CD33*CD3 BsAb
- Where
- 13 sites in United States
- Volunteers
- 3 people
- Sponsor
- Y-mAbs Therapeutics
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Breast Cancer, Chronic Myeloproliferative Disorders
Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon
RATIONALE: Beclomethasone may be an effective treatment for graft-versus-host disease. PURPOSE: Phase I/II trial to study the effectiveness of beclomethasone in treating patients who have graft-versus-host disease of the…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00010283
- Testing
- beclomethasone dipropionate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA CAR-NK cell injection in patients with refractory pediatric rheumatic diseases.
- Conditions
- Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus Erythematosus (SLE), Connective Tissue Disease-associated Interstitial Lung Disease
- Trial name
- Cell therapy (NCT07490041)
- Testing
- KN5601
- Where
- China
- Volunteers
- 36 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Medulloblastoma, Central Nervous System Embryonal Tumor
GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults
This is a single-site, open-label Phase I treatment study evaluating the manufacturing feasibility and safety of chimeric antigen receptor (CAR) T cells targeting the oncofetal protein Glypican-2 (GPC2) in pediatric and young…
- Conditions
- Medulloblastoma, Central Nervous System Embryonal Tumor, Refractory Medulloblastoma, Recurrent Medulloblastoma
- Trial name
- NCT07087002
- Testing
- GPC2-CAR T cells, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Relapsing-Remitting Multiple Sclerosis
An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients
This was an observational, single arm, multicentric study conducted for the adjustment of treatment strategy and its monitoring using high-frequency and high-dosage administration of interferon-beta (Rebif) in MS subjects.
- Trial name
- NCT01142453
- Testing
- Interferon beta 1a
- Volunteers
- 231 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Metastatic Ewing Sarcoma, Metastatic Osteosarcoma
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
This phase II trial studies how well cabozantinib s-malate works in treating patients with osteosarcoma or Ewing sarcoma that has grown or returned (come back) after a period of improvement.
- Conditions
- Metastatic Ewing Sarcoma, Metastatic Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma
- Trial name
- NCT02243605
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Sclerosis
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour
Introduction: Fetal exposure to glucocorticoids (GCs) used to induce fetal lung maturation in women threatened by premature labour is known to induce aberrations in brain development and stress sensitivity, cognitive dysfunction…
- Trial name
- MS-Children (NCT04832269)
- Testing
- Exposure to methylprednisolone during pregnancy
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Jena University Hospital
Nephrotic Syndrome
Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome
Idiopathic nephrotic syndrome is generally responsive to steroid therapy, but some patients need other immunosuppressants to reduce steroid dependency.
- Trial name
- NCT01895894
- Testing
- Mycophenolate mofetil
- Where
- South Korea
- Volunteers
- 34 people
- Sponsor
- Seoul National University Hospital
Effect of Drug, Toxicity, Drug
Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma
Today, using a multi-modal approach consisting of preoperative (neoadjuvant) systemic polychemotherapy followed by local surgical therapy and then postoperative (adjuvant) chemotherapy, long-term, disease-free survival can be…
- Conditions
- Effect of Drug, Toxicity, Drug, Secondary Resistance
- Trial name
- NCT04690231
- Testing
- Apatinib Mesylate, ifosfamide and etoposide
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Peking University People's Hospital
Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute
Phase I, Dose Escalation Study of Decitabine
Decitabine is a hypomethylating agent that has shown significant anti-leukemic effect in Myelodysplastic Syndrome (MDS) and Acute Myeloblastic Leukemia (AML).
- Conditions
- Leukemia, Lymphoblastic, Acute, Leukemia, Myeloid Acute, Hematopoetic Myelodysplasia
- Trial name
- NCT02264873
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Florida
Hematological Malignancies
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
This is a open-label, phase 2 study to evaluate the efficacy, safety and PK of CD7 chimeric antigen receptors treatment for patients with refractory/relapsed CD7 positive hematological malignancies.
- Trial name
- NCT05454241
- Testing
- Anti-CD7 CAR-T
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05309213
- Testing
- IM19 CAR-T cells
- Volunteers
- 58 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Leukaemia, Lymphocytic, Chronic
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy
The purpose of this study was to determine if maintenance therapy with ofatumumab would prolong remission in patients with CLL who have responded to second or third line treatment.
- Trial name
- PROLONG (NCT01039376)
- Testing
- Ofatumumab, Observation
- Where
- 203 sites in United States, Argentina and 23 more
- Volunteers
- 480 people
- Sponsor
- Novartis Pharmaceuticals
Ewing Sarcoma
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
The main objectives of this trial are to determine the recommended dose for expansion of xaluritamig (dose confirmation part only) and to determine the safety and tolerability of xaluritamig in adult, adolescent and pediatric…
- Trial name
- NCT07297979
- Testing
- Xaluritamig
- Where
- 13 sites in United States, Australia
- Volunteers
- 50 people
- Sponsor
- Amgen
Pediatric Solid Tumor, Neuroblastoma
B7-H3.CD28Z.CART in Solid Tumors
The goal of this research study is to test if a new cell therapy (B7-H3.CD28Z.CART / B7-H3 CAR T cells) is safe and effective in treating children and young adults with solid cancers whose tumors have returned or stopped…
- Trial name
- NCT07358260
- Testing
- B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Robbie Majzner
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)
This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.
- Trial name
- NCT04034446
- Testing
- CD19-CD22 CAR-T cells
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.